Establishment and Characterization of a New Intrahepatic Cholangiocarcinoma Cell Line, ICC-X2

被引:2
作者
Tang, Huan
Luo, Wei
Zhang, Hui
Miao, Xin
机构
[1] The Fourth Department of General Surgery, The First Hospital of Lanzhou University, Lanzhou
[2] The First Clinical Medical College, Lanzhou University, Lanzhou
[3] The Second Clinical Medical College, Lanzhou University, Lanzhou
[4] Department of Anesthesiology, Lanzhou University Second Hospital, Lanzhou
[5] Department of Surgery, The First School of Clinical Medicine of Gansu University of Chinese Medicine, Lanzhou
[6] Department of General Surgery, Lanzhou University Second Hospital, Lanzhou
[7] State Key Laboratory of Veterinary Etiological Biology, Key Laboratory of Animal Virology of the Ministry of Agriculture, Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Lanzhou
基金
中国国家自然科学基金;
关键词
Intrahepatic cholangiocarcinoma; Cell line; Establish-ment; Xenograft; Animal model;
D O I
10.14740/wjon1757
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Intrahepatic cholangiocarcinoma (ICC) is an aggressive malignant tumor of the biliary tract that is prone to recurrence and metastasis and is characterized by poor sensitivity to chemotherapy and overall prognosis. For these reasons, there is an urgent need to understand its pathological mechanisms and develop effective treatments. To address this challenge, the establishment of suitable preclinical models is critical. Methods: Fresh ICC tissue samples were used for primary culture and subculture. The cell line was evaluated by cell proliferation assays, clonal formation assays, karyotype analysis, and short tandem repeat (STR) analysis. Drug resistances against oxaliplatin, paclitaxel, gemcitabine and 5-fluorouracil (5-FU) were evaluated by CCK-8 assay. Subcutaneous injection of 1 x 106 cells to three BALB/c nude mice was conducted for xenograft studies. The hematoxylin and eosin (H&E) staining was used to detect the pathological status of the cell line. The expression of biomarkers CK7, CK19, Ki-67, E-cadherin and vimentin was determined by immunocytochemistry assay. Results: A new ICC cell line named ICC-X2 was successfully established. Like ICC-X3 established using the same patient's metastatic tumor, the cell line has been continuously cultured in vitro for more than a year and has been passaged more than 100 times. ICC-X2 retained the typical biliary epithelial morphology. The population doubling time of ICC-X2 is 48 h. The cells demonstrated an abnormal nearly tetraploid karyotype. The STR analysis confirmed that ICC-X2 was highly consistent with the primary tumor tissue and not cross-contaminated by existing cell lines. ICC-X2 cells positively expressed CK7, CK19, E-cadherin, and vimentin, and the positive expression of Ki-67 in ICC-X2 cells was 40%. The ICC-X2 cells exhibited a strong clonogenic ability. The drug sensitivity test indicated that ICC-X2 was sensitive to oxaliplatin and paclitaxel, but naturally resistant to gemcitabine and 5-FU. ICC-X2 was rapidly able to form transplanted tumors in vivo after subcutaneous inoculation in nude mice. Conclusions: ICC-X2 is an excellent experimental model that can be used for studying the occurrence, development, and metastasis of ICC and investigating the mechanism of tumor drug resistance.
引用
收藏
页码:114 / 125
页数:12
相关论文
共 31 条
[1]  
Valle JW, Kelley RK, Nervi B, Oh DY, Zhu AX., Biliary tract cancer, Lancet, 397, 10272, pp. 428-444, (2021)
[2]  
Kudo M, Izumi N, Kokudo N, Sakamoto M, Shiina S, Takayama T, Tateishi R, Et al., Report of the 22nd nationwide follow-up Survey of Primary Liver Cancer in Japan (2012-2013), Hepatol Res, 52, 1, pp. 5-66, (2022)
[3]  
Sakamoto Y, Kokudo N, Matsuyama Y, Sakamoto M, Izumi N, Kadoya M, Kaneko S, Et al., Proposal of a new staging system for intrahepatic cholangiocarcinoma: Analysis of surgical patients from a nationwide survey of the Liver Cancer Study Group of Japan, Cancer, 122, 1, pp. 61-70, (2016)
[4]  
Dover LL, Jacob R, Wang TN, Richardson JH, Redden DT, Li P, DuBay DA., Improved postoperative survival for intraductal-growth subtype of intrahepatic cholangio-carcinoma, Am Surg, 82, 11, pp. 1133-1139, (2016)
[5]  
Fong ZV, Brownlee SA, Qadan M, Tanabe KK., The clinical management of cholangiocarcinoma in the United States and Europe: a comprehensive and evidence-based comparison of guidelines, Ann Surg Oncol, 28, 5, pp. 2660-2674, (2021)
[6]  
Mavros MN, Economopoulos KP, Alexiou VG, Pawlik TM., Treatment and prognosis for patients with intrahe-patic cholangiocarcinoma: systematic review and metaanalysis, JAMA Surg, 149, 6, pp. 565-574, (2014)
[7]  
Mazzaferro V, Gorgen A, Roayaie S, Droz Dit Busset M, Sapisochin G., Liver resection and transplantation for intrahepatic cholangiocarcinoma, J Hepatol, 72, 2, pp. 364-377, (2020)
[8]  
Zhang XF, Beal EW, Bagante F, Chakedis J, Weiss M, Popescu I, Marques HP, Et al., Early versus late recurrence of intrahepatic cholangiocarcinoma after resection with curative intent, Br J Surg, 105, 7, pp. 848-856, (2018)
[9]  
Zhang XF, Xue F, He J, Alexandrescu S, Marques HP, Aldrighetti L, Maithel SK, Et al., Proposed modification of the eighth edition of the AJCC staging system for intrahepatic cholangiocarcinoma, HPB (Oxford), 23, 9, pp. 1456-1466, (2021)
[10]  
Zhang XF, Xue F, Dong DH, Weiss M, Popescu I, Marques HP, Aldrighetti L, Et al., Number and station of lymph node metastasis after curative-intent resection of intrahepatic cholangiocarcinoma impact prognosis, Ann Surg, 274, 6, pp. e1187-e1195, (2021)